Family Medicine Perspective

• Phase 1 Trials: Are We Using Optimal Drug Dose Schedules?   David J. Kerr, CBE, MD, DSc, discusses considerations for dosing schedules in Phase 1 trials.
  Medscape Oncology, December 28, 2023
  1
• Advances in Acute Lymphoblastic Leukemia From ASH 2023   Chemotherapy-free regimens in Philadelphia chromosome–positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.
  Medscape, December 28, 2023
• Most Popular Stories of 2023: Primary Care Edition New vaccines, sex and older adults, blood pressure targets, and physician shortage topped our list of most popular stories.
  Medscape Family Medicine, December 27, 2023
• Highlights in HR-Positive Breast Cancer From SABCS 2023   Highlights in HR+/HER2- breast cancer from SABCS 2023 include the INAVO120 trial of novel PI3K inhibitor inavolisib and 3-year follow-up data from the NATALEE trial, as reported by Dr Harold Burstein.
  Medscape, December 27, 2023
• 'Shower' Me for My Medical Expertise A recent article criticized Wegovy's manufacturers for "showering" doctors with money. Beverly Tchang, MD, explains why doctors shouldn't be ashamed of receiving consulting fees for their expertise.
  Medscape Diabetes & Endocrinology, December 27, 2023
  8
• Are You Employing Genetic Testing Correctly for CRC?   The latest guidelines and data support wider use of germline testing for certain patients, says Dr David Johnson.
  Medscape Gastroenterology, December 27, 2023
  1
• The Ethics of Sham PCI and Clinical Relevance of ORBITA-2   John Mandrola asks Rasha Al-Lamee and Christopher Rajkumar to address criticisms of the ethics and clinical relevance of their pivotal ORBITA-2 trial.
  theheart.org on Medscape, December 27, 2023
• The Clinical Implications of Findings From SABCS 2023   Dr Tarah J. Ballinger explores the impact of the INAVO120 study and the NATALEE trial on HR+/HER2- metastatic breast cancer.
  Medscape, December 27, 2023
• Chronic Lymphocytic Leukemia Highlights From ASH 2023   Doublet and triplet therapies as well as strong results from late-generation BTK inhibitors and sequencing are among CLL highlights from ASH 2023, as reported by Dr John Allan.
  Medscape, December 26, 2023
• The 2024 Adult Vaccine Schedule Changes Are Here   Usually posted in February, the 2024 schedule has arrived early. Dr Sandra Fryhofer goes over the key changes in the adult schedule for 2024.
  Medscape Internal Medicine, December 26, 2023
  51
• Technology for Primary Care — Terrific, Terrifying, or Both? The paper appointment book has been replaced by scheduling systems sometimes lacking in flexibility for double booking, sibling visits, and variable length.
  MDedge, December 22, 2023
  1
• New Study on Colic Suggests Longer-Term Implications Findings from a study of nearly 5000 children, from before birth to adolescence, challenges traditional thinking.
  MDedge, December 22, 2023
  2
• CPAP Oversells and Underperforms The pressure pushers have been undeterred by evidence, says Dr Holley.
  Medscape Critical Care, December 22, 2023
  92
• Metastatic Breast Cancer Treatment: What the Future Holds Dr Eric Winer discusses the current state of metastatic breast cancer therapies and what the future holds, as clinicians strive to optimize patient care.
  Medscape Oncology, December 22, 2023
• Lifesaving Surgery for Lungless Man   Surgical creativity and a dash of DIY helped Chicago-area man beat a devastating pulmonary infection that destroyed both of his lungs.
  Medscape, December 21, 2023
  9
• This Is Your Brain on Zoom Neurologist Leah Croll reviews a novel brain imaging study showing that virtual interactions don't access the brain's social neural pathways as effectively as live interactions.
  Medscape Neurology, December 21, 2023
  10
• Benign Ovarian Cysts: Will They Resolve Spontaneously?   Benign Ovarian Cysts: Will They Resolve Spontaneously?
  Medscape Ob/Gyn, December 21, 2023
  2
• Clinician Duties During Times of Geopolitical Conflict Clinicians are increasingly confronted with ethical dilemmas that extend far beyond what is outlined in our code of ethics.
  MDedge, December 21, 2023
• Is It Possible to Predict the Risk for Pancreatic Cancer? A US-based team seeks to develop and validate a model allowing clinicians to predict the risk for pancreatic cancer.
  MDedge, December 21, 2023
  7
• AI in Oncology: Sorting Through Misinformation   David J. Kerr, CBE, MD, DSc, discusses the use of artificial intelligence in oncology now and in the future.
  Medscape Oncology, December 21, 2023